Boehringer Ingelheim Acquires Evax to Expand Equine Health
Ingelheim, Germany, August,11, 2026 Boehringer Ingelheim has acquired Evax AG, a Swiss biotechnology company focused on equine health, expanding...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Ingelheim, Germany, August,11, 2026 Boehringer Ingelheim has acquired Evax AG, a Swiss biotechnology company focused on equine health, expanding...
Amsterdam, the Netherlands, August,11, 2026 Royal Philips and Exor N.V. have agreed to update their long-term relationship agreement, reinforcing...
Amsterdam, Netherlands, August 7, 2026 Royal Philips has expanded its open patient monitoring ecosystem through a series of strategic...
AMSTERDAM, the Netherlands, March 3, 2026 The SHERPA research consortium, coordinated by Royal Philips, has initiated seven clinical studies...
